Cancer death (non-skin) 2.3 X more likely if low Vitamin D

Created August 2021

Serum 25-Hydroxyvitamin D and Subsequent Cancer Incidence and Mortality: A Population-Based Retrospective Cohort Study

Mayo Clin Proc. 2021 Aug;96(8):2157-2167. doi: 10.1016/j.mayocp.2020.12.037.

Casey R Johnson 1, Daniel V Dudenkov 2, Kristin C Mara 3, Philip R Fischer 4, Julie A Maxson 5, Tom D Thacher 5

* 8 ways that Cancer might be prevented by Vitamin D - June 2019 * Vitamin D prevents and treats cancer in many ways – May 2021 * Children's Cancer hospital now testing vitamin D frequently and supplementing weekly – July 2021 * Vitamin D fights 13 cancers – review of 35 meta-analyses – Oct 2020 * Those with recent cancer diagnosis had 7X increased risk of COVID-19 (more if A-A )- Dec 2020 1. Items in both categories Cancer and Mortality: {category} 1. Cancer category starts with the following {include} 1. Low D in the blood is important, but perhaps more important is low D in cells due to poor VDR * Cancer is leading cause of death - Vitamin D and Receptor activators help * Cancer and the Vitamin D Receptor, a primer – Sept 2017 The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019 * Omega-3,  Magnesium, Zinc,  Quercetin,  non-daily Vit D,  Curcumin, intense exercise,   Ginger,   Essential oils, etc**  Note: The founder of VitaminDWiki uses 10 of the 13 known VDR activators

Objective: To determine the relationship between 25-hydroxyvitamin D (25[OH]D) values and subsequent cancer incidence and mortality.

Patients and methods: We identified all adult patients living in Olmsted County, Minnesota, between January 1, 2005, and December 31, 2011, who had at least 1 25(OH)D measurement and no prior diagnosis of cancer. Cancer outcomes were retrieved starting 30 days after 25(OH)D measurement and until patients' final clinical visit as an Olmsted County resident; December 31, 2014; or death. Cox proportional hazards regression was used to analyze data.

Results: A total of 8700 individuals had a 25(OH)D measurement and no history of cancer, with a mean ± SD 25(OH)D value of 29.7±12.8 ng/mL (to convert to nmol/L, multiply by 2.496). The mean ± SD age was 51.5±16.4 years, and most were women (78.1%; n=6796) and White (85.7%; n=7460). A total of 761 individuals developed cancer (skin cancer, n=360; nonskin cancer, n=401) during a median follow-up of 4.6 (interquartile range, 3.4-6.1) years.

Compared with participants with 25(OH)D values of 20 to 50 ng/mL (reference group), those with 25(OH)D values less than 12 ng/mL had a greater nonskin cancer incidence (hazard ratio [HR], 1.56; 95% CI, 1.03 to 2.36; P=.04) after adjustment.

There was no association between 25(OH)D values and total cancer or skin cancer incidence.

Compared with individuals from the reference group, 25(OH)D levels less than 12 ng/mL ( HR, 2.3 ; 95% CI, 1.01 to 5.48; P=.047)

and 12 to 19 ng/mL (HR, 2.10; 95% CI, 1.05 to 4.22; P=.04) were associated with increased cancer mortality.

Conclusion: Low 25(OH)D levels were associated with increased risk for incident nonskin cancer and cancer-related mortality.

Tags: Cancer Mortality